article Open AccessTop 1% cited
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
The Lancet Infectious Diseases · 2020 · Vol. 21(1) · pp. 39–51
Shengli Xia✉(Henan Provincial Center for Disease Control and Prevention)Yuntao Zhang(National Vaccine and Serum Institute)Yanxia Wang(Henan Provincial Center for Disease Control and Prevention)Hui Wang(National Vaccine and Serum Institute)Yunkai Yang(National Vaccine and Serum Institute)George F. Gao(Chinese Center For Disease Control and Prevention)Wenjie Tan(Chinese Center For Disease Control and Prevention)Guizhen Wu(Chinese Center For Disease Control and Prevention)Miao Xu(National Institutes for Food and Drug Control)Zhiyong Lou(Tsinghua University)Weijin Huang(National Institutes for Food and Drug Control)Wenbo Xu(Chinese Center For Disease Control and Prevention)Baoying Huang(Chinese Center For Disease Control and Prevention)Huijuan Wang(National Vaccine and Serum Institute)Wei Wang(National Vaccine and Serum Institute)Wei Zhang(Henan Provincial Center for Disease Control and Prevention)Na Li(National Vaccine and Serum Institute)Zhiqiang Xie(Henan Provincial Center for Disease Control and Prevention)Ling Ding(National Vaccine and Serum Institute)Wangyang You(Henan Provincial Center for Disease Control and Prevention)Yuxiu Zhao(National Vaccine and Serum Institute)Xuqin Yang(National Vaccine and Serum Institute)Yang Liu(National Vaccine and Serum Institute)Qian Wang(National Vaccine and Serum Institute)Lili Huang(Henan Provincial Center for Disease Control and Prevention)Yongli Yang(Zhengzhou University)Guangxue Xu(Tsinghua University)Bojian LuoWen‐Ching Wang(Chinese Center For Disease Control and Prevention)Peipei Liu(Chinese Center For Disease Control and Prevention)Wanshen Guo(Henan Provincial Center for Disease Control and Prevention)Xiaoming Yang(National Vaccine and Serum Institute)
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approachesMedicinePlaceboImmunogenicityTolerabilityClinical trialRandomized controlled trialInternal medicineAdverse effectImmunologyAntibody
Citations
1,207
FWCI
27.09
field-weighted impact
References
20
Percentile
100%
vs. same field & year
Citations per year
Cited by
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
The Lancet Infectious Diseases · 2020 · 1,500 citations
References
A novel coronavirus outbreak of global health concern
The Lancet · 2020 · 8,079 citations
A Novel Coronavirus from Patients with Pneumonia in China, 2019
New England Journal of Medicine · 2020 · 30,188 citations
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
The Lancet · 2020 · 22,618 citations
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
The Lancet · 2020 · 9,576 citations
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
New England Journal of Medicine · 2020 · 17,893 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.